H World Group Accelerates Hotel Expansion and Brand Upgrades in Q1 2025, Strengthens Position as Hospitality Leader
SINGAPORE and SHANGHAI, China, May 20, 2025 /PRNewswire/ -- H World Group Limited (NASDAQ: HTHT) (HK: 01179), one of the world's leading hospitality groups, began 2025 with continued momentum in growth, asset-light transformation and brand loyalty, according to its first-quarter results released today.
A Scalable Model for Mass-Market HospitalityH World Group achieved 538 net hotel openings in the first quarter ended March 31, taking the total number of hotels in operation to 11,685. The number of rooms worldwide totaled 1,142,158, a 20% increase over last year.
The company now covers 1,394 cities across China, with plans to reach 2,000 cities in the future – from major hubs to the most remote and underserved regions.As of March 31, H World had a total of 2,888 hotels in its pipeline.
Advancing the Asset-Light TransformationH World continued to advance its asset-light strategy in this quarter, with revenue from manachised and franchised hotels rising 21% year-over-year to RMB 2.5 billion (US$344 million). The company's distinct manachise model — combining the scalability of franchising with the operational control of management — remains a key enabler of efficient, brand-consistent growth.
Loyalty Growth & Direct Booking StrengthAs of the end of Q1, H Rewards membership reached 277 million, making it one of the largest loyalty platforms in the global hospitality industry. Direct booking from members accounted for over 65% of total reservations – a 5.4 percentage point increase year-on-year, reflecting growing digital engagement, improved margins, and greater customer lifetime value.
Ongoing Experience UpgradeH World continued to advance its product upgrade initiatives to enhance consumer experience across core brands including Hanting, JI, and Orange. As of Q1:
40% of Hanting Hotels had reached version 3.5 or above
78% of Ji Hotels had reached Ji 4.0+
70% of Orange Hotels met the Orange 2.0 standard
The first quarter also marked rapid growth in the upper-midscale segment, which includes brands such as Intercity Hotel, Crystal Orange Hotel, MAXX by Steigenberger, and CitiGo Hotel, with a 36% year-on-year increase in operating hotels and a 22% expansion of the development pipeline.
Looking Ahead"We are confident we will achieve our full-year network expansion target of approximately 2,300 gross hotel openings," said H World CEO Jin Hui. "To achieve sustainable long-term growth, we will continue advancing our asset-light strategy, focusing on high-quality network expansion, enhancing brand positioning and 'service excellence', and strengthening sales capabilities centred around our H Rewards membership program."
For the full release please visit:https://ir.hworld.com/news-releases/news-release-details/h-world-group-limited-reports-first-quarter-2025-unaudited
1. The conversion of Renminbi ("RMB") into United States dollars ("US$") is based on the exchange rate of US$1.00=RMB7.2567 on March 31, 2025, as set forth in H.10 statistical release of the U.S. Federal Reserve Board and available at http://www.federalreserve.gov/releases/h10/hist/dat00_ch.htm.
About H World Group Limited
Originated in China, H World Group Limited (NASDAQ:HTHT; HK:01179) is a key player in the global hotel industry. H World's brands include HanTing Hotel, JI Hotel, Crystal Orange Hotel, Steigenberger Hotels & Resorts, MAXX, Jaz in the City, IntercityHotel, Zleep Hotels and Steigenberger Icons. In addition, H World also has the rights as master franchisee for Mercure, Ibis and Ibis Styles, and co-development rights for Grand Mercure and Novotel, in the pan-China region.
For more information, please visit H World's website: https://ir.hworld.com
H World undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.
For media inquiry, please contact:
Lihuan Wang media@hworld.comZheming Xing zheming@taskforce-china.cnZhibin Lang zhibin.lang@taskforce-china.cn
View original content to download multimedia:https://www.prnewswire.com/news-releases/h-world-group-accelerates-hotel-expansion-and-brand-upgrades-in-q1-2025-strengthens-position-as-hospitality-leader-302460519.html
SOURCE H World Group
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 minutes ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Insider
17 minutes ago
- Business Insider
RBC Capital Sticks to Its Hold Rating for CME Group (CME)
RBC Capital analyst Ashish Sabadra maintained a Hold rating on CME Group (CME – Research Report) on June 8 and set a price target of $269.00. The company's shares closed yesterday at $268.35. Confident Investing Starts Here: Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. According to TipRanks, Sabadra has an average return of 6.1% and a 62.50% success rate on recommended stocks. In addition to RBC Capital, CME Group also received a Hold from KBW's Kyle Voigt in a report issued on June 4. However, on the same day, Oppenheimer reiterated a Buy rating on CME Group (NASDAQ: CME). CME market cap is currently $98.82B and has a P/E ratio of 27.57. Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CME in relation to earlier this year. Last month, Daniel Kaye, a Director at CME sold 500.00 shares for a total of $141,205.00.
Business Insider
17 minutes ago
- Business Insider
Nasdaq (NDAQ) Gets a Buy from RBC Capital
RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) on June 8 and set a price target of $95.00. The company's shares closed yesterday at $85.65. Confident Investing Starts Here: According to TipRanks, Sabadra is a 5-star analyst with an average return of 6.1% and a 62.50% success rate. Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. Currently, the analyst consensus on Nasdaq is a Moderate Buy with an average price target of $84.58. NDAQ market cap is currently $49.15B and has a P/E ratio of 38.82. Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NDAQ in relation to earlier this year. Last month, Pc Nelson Griggs, the Pres. Capital Access Platforms of NDAQ sold 8,000.00 shares for a total of $664,240.00.
